Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Grupo de trabajo de la guía de práctica clínica sobre ERGE. Manejo del paciente con enfermedad por reflujo gastroesofágico (ERGE). Guía de práctica clínica. Barcelona: Asociación Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria y Centro Cochrane Iberoamericano; 2001. Programa de elaboración de Guías de Práctica Clínica en Enfermedades Digestivas, desde la Atención Primaria a la Especializada: 1.
[2.]
J. Dent, H.B. El-Serag, M.-A. Wallander, S. Johansson.
Epidemiology of gastro-oesophageal reflux disease: a systematic review.
Gut, 54 (2005), pp. 710-717
[3.]
J. Ponce, O. Vegazo, B. Beltrán, J. Jimenez, J. Zapardiel, D. Calle, et al.
Prevalence of gastro-oesophageal reflux disease in Spain and associated factors.
Aliment Pharmacol Ther, 23 (2006), pp. 175-183
[4.]
R. Carlsson, J. Dent, R. Watts, S. Riley, R. Sheikh, J. Hatlebakk, et al.
Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.
Eur J Gastroenterol Hepatol, 10 (1998), pp. 119-124
[5.]
R. Garside, M. Pitt, M. Somerville, K. Stein, A. Price, N. Gilbert.
Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Health Technol Assess, 10 (2006), pp. 8
[6.]
H. Liker, P. Hungin, I. Wiklund.
Managing gastroesophageal reflux disease in primary care: the patient perspective.
J Am Board Fam Pract, 18 (2005), pp. 393-400
[7.]
D.A. Revicki, M. Wood, P.N. Maton, S. Sorensen.
The impact of gastroesophageal reflux disease on health-related quality of life.
Am J Med, 104 (1998), pp. 252-258
[8.]
M. Ponce, F. Calvo, A. Palau, J. Ponce.
Calidad de vida y ERGE.
Gastroenterol Hepatol, 24 (2001), pp. 9-15
[9.]
I. Wiklund.
Quality of life in patients with gastroesophageal reflux disease.
Am J Gastroenterol, 96 (2001), pp. 46S-53S
[10.]
I. Wiklund.
Review of the quality of life and burden of illness in gastroesophageal reflux disease.
Dig Dis, 22 (2004), pp. 108-114
[11.]
E.M.M. Quigley, A.P.S. Hungin.
Quality-of-life sigues in gastrooesophageal reflux disease.
Aliment Phamracol Ther, 22 (2005), pp. 41-47
[12.]
I.M. Gralnek, R.D. Hays, A. Kilbourne, B. Naliboff, E.A. Mayer.
The impact of irritable bowel syndrome on health-related quality of life.
Gastroenterology, 119 (2000), pp. 654-660
[13.]
M.A. Eloubeidi, D. Provenzale.
Health-related quality of life and severity of symptoms in patients with Barretts's esophagus ad gastroesophageal reflux disease patients without Barrett's esophagus.
Am J Gastroenterol, 95 (2000), pp. 1881-1887
[14.]
C. Farup, L. Kleinman, S. Sloan, D. Ganoczy, E. Chee, C. Lee, et al.
The impact of nocturnal symptoms associate with gastroesophageal reflux disease on health-related quality of life.
Arch Intern Med, 161 (2001), pp. 45-52
[15.]
R. Shaker, D.O. Castell, P. Schoenfeld, S.J. Spechler.
Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterology Association.
Am J Gastroenterol, 98 (2003), pp. 1487-1493
[16.]
W.C. Orr.
Sleep and gastroesophageal reflux: what are the risks?.
Am J Med, 115 (2003), pp. 109-113
[17.]
D.A. Revicki, M.W. Zodet, S. Joshua-Gotlib, D. Levine, J.A. Crawley.
Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity.
Health Qual Life Outcomes, 1 (2003), pp. 73
[18.]
A.J.P.M. Smout.
Endoscopy-negative acid reflux disease.
Aliment Pharmacol Ther, 11 (1997), pp. 81-85
[19.]
I. Wiklund, K.D. Bardhan, S. Müller-Lissner, M.A. Bigard, G. Bianchi Porro, J. Ponce, et al.
Quality of life during acute and intermittent treatment of gastroesophageal reflux disease with omeprazole compared with ranitidine. Results from a multi-center clinical trial.
Ital J Gastroenterol Hepatol, 30 (1998), pp. 19-27
[20.]
M. Kulig, A. Leodolter, M. Vieth, E. Schulte, D. Jaspersen, J. Labenz, et al.
Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease: an analysis based on the ProGERD initiative.
Aliment Pharmacol Ther, 18 (2003), pp. 767-776
[21.]
J. Ponce, L. Argüello, G. Bastida, M. Ponce, V. Ortiz, V. Garrigues.
On-demand therapy with rabeprazole in nonerosive and erosive gastro-oesophageal reflux disease in clinical practice: effectiveness, health-related quality of life and patient satisfaction.
Dig Dis Sci, 49 (2004), pp. 931-936
[22.]
D.A. Johnson, W.C. Orr, J.A. Crawley, B. Traxter, J. McCullough, K.A. Brown, et al.
Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: a randomized placebocontrolled trial.
Am J Gastroenterol, 100 (2005), pp. 1914-1922
[23.]
D.A. Revicki, J.A. Crawley, M.W. Zodet, D.S. Levine, B.O. Joelsson.
Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease.
Aliment Pharmacol Ther, 13 (1999), pp. 1621-1630
[24.]
S.N. Willich, M. Nocon, M. Kulig, D. Jaspersen, J. Labenz, W. Meyer-Sabellek, et al.
Cost-of-disease analysis in patients with gastro-oesophageal reflux disease and Barrett's mucosa.
Aliment Pharmacol Ther, 23 (2006), pp. 371-376
[25.]
E. Rey, C. Moreno Elola-Olaso, F. Rodríguez Artalejo, M. Díaz-Rubio, et al.
Impact of gastroesophageal reflux symptoms on health resource usage and work absenteeism in Spain.
Rev Esp Enferm Dig, 98 (2006), pp. 518-526
[26.]
P. Wahlqvist, J. Carlsson, N.O. Stalhammar, I. Wiklund.
Measuring lost productivity in patients with GERD using a productivity questionnaire (WPAI-GORD).
Qual Life Res, 8 (1999), pp. 576
[27.]
P. Wahlqvist.
Symptoms of gastroesophageal reflux disease, perceived productivity, and health-related quality of life.
Am J Gastroenterol, 96 (2001), pp. 57-61
[28.]
J. Mason, A.P.S. Hungin.
Gastro-oesophageal reflux disease: the health economic implications.
Aliment Pharmacol Ther, 22 (2005), pp. 20-31
[29.]
B.B. Dean, J.A. Crawley, C.M. Schmitt, J. Wong, J.J. Ofman.
The burden of illness of gastro-oesophageal reflux disease: impact on work productivity.
Aliment Pharmacol Ther, 17 (2003), pp. 1309-1317
[30.]
P. Wahlqvist, J. Carlsson, N.O. Stalhammar, I. Wiklund.
Validity of a work productivity and activity impairment questionnaire for patients with symptoms of gastro-esophageal reflux disease (WPAI-GERD). Results from a cross-sectional study.
Value Health, 5 (2002), pp. 106-113
[31.]
B.S. Bloom, R. Jayadevappa, P. Wahl, J. Cacciamanni.
Time trends in cost of caring for people with gastroesopahgeal reflux disease.
Am J Gastroenterol, 98 (2001), pp. 64-69
[32.]
J. Dent, J. Brun, A.M. Fendricks, M.B. Fennerty, J. Janssens, P.J. Kahrilas, et al.
An evidence-based appraisal of reflux disease management. The Genval workshop report.
Gut, 44 (1999), pp. 1-16
[33.]
J. Dent, D. Armstrong, B. Delaney, P. Moayyedi, N.J. Talley, N. Vakil.
Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and disussion outpouts.
Gut, 53 (2004), pp. 1-24
[34.]
N. Vakil, S.V. Van Zasten, P. Kahrilas, J. Dent, R. Jones.
Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus.
Am J Gastroenterol, 101 (2006), pp. 1900-1920
[35.]
R. Carlsson, J. Dent, E. Bolling-Sternevald, F. Johnsson, O. Junghard, K. Lauritsen, et al.
The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal disease.
Scand J Gastroenterol, 33 (1998), pp. 1023-1029
[36.]
K.R. DeVault, D.O. Castell.
Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease.
Am J Gastroenterol, 100 (2005), pp. 190-200
[37.]
N. Vakil.
Review article: test and treat or treat and test in reflux disease?.
Aliment Pharmacol Ther, 17 (2003), pp. 57-59
[38.]
J. Dent, N.J. Talley.
Overview: initial and long-term management of gastro-oesophageal reflux disease.
Aliment Pharmacol Ther, 17 (2003), pp. 53-57
[39.]
R.C. Heading.
Review article: diagnosis and clinical investigation of gastro-oesophageal reflux disease: a European view.
Aliment Pharmacol Ther, 20 (2004), pp. 9-13
[40.]
N. Sharma, C. Donnellan, C. Preston, B. Delaney, G. Duckett, P. Moayyedi.
A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.
Gut, 53 (2004), pp. 58-65
[41.]
D.A. Revicki.
Patient assessment of treatment satisfaction: methods and practical issues.
Gut, 53 (2004), pp. 40-44
[42.]
M.E. Numans, J. Lau, N.J. De Wit, P.A. Bonis.
Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic tets characteristics.
Ann Intern Med, 140 (2004), pp. 518-527
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
